Early cholesterol treatment in kids may prevent heart disease for life

Key Point for Families and Grandparents

In a large computer simulation of children with a genetic cholesterol disorder called familial hypercholesterolemia (FH):

• Starting cholesterol-lowering treatment around age $10$ and continuing it for life led to the lowest lifetime risk of heart attack and stroke and about half as many cardiovascular events as those who never received treatment.
• Delaying treatment or stopping it in young adulthood led to higher lifelong cholesterol exposure, more heart disease events, and fewer years lived on average.

What Is Familial Hypercholesterolemia (FH)?

Familial hypercholesterolemia is an inherited condition that causes very high LDL (“bad”) cholesterol from a young age.

• People with FH often have LDL levels much higher than normal even as children.
• Without treatment, they face a much higher risk of early heart disease, sometimes in their 30s, 40s, or 50s.
• FH often runs in families: if a parent has it, each child has about a $50\%$ chance of inheriting it.

For seniors, this may explain why some relatives had heart attacks or needed procedures at relatively young ages and underscores the value of testing younger family members.

How the Study Was Done

Researchers used a computer simulation model rather than following real patients for decades. They focused on children in the United States with heterozygous FH (the commoner, less severe form).

• The model simulated the health of $100{,}000$ children aged $10$ with FH, representing roughly $15{,}900$ real children over their lifetimes, and followed outcomes across ages $2$ to $100$.
• Six strategies were compared:
  1. No treatment
  2. Usual care (typical real-world patterns, including delays or interruptions)
  3. Start lipid-lowering therapy at age $10$ and continue for life
  4. Start therapy at age $18$ and continue for life
  5. Start at age $10$, interrupt at $18$, then transition to usual care
  6. Start at age $10$, then permanently stop at $18$
• Outcomes included lifetime LDL exposure (mg/dL-years), cardiovascular events (CVD), life years, quality-adjusted life years, and therapy-related side effects.
• The model was run $100$ times to produce 95% uncertainty ranges, giving a sense of result variability.

Key Findings

1. Lifelong treatment started in childhood gave the best outcomes

Children with FH who never received treatment had an average cumulative LDL exposure of about $14{,}921$ mg/dL-years over their lifetimes. Starting therapy at $10$ and continuing for life substantially reduced this exposure.

Compared with no treatment, early and continuous therapy:

• Prevented about $10{,}754$ cardiovascular events (95% UI: $10{,}188$–$11{,}343$).
• Added about $54{,}136$ life years (95% UI: $48{,}597$–$58{,}218$).

2. Heart disease risk was nearly cut in half

Over a lifetime:

• Untreated children with FH had about $22.4$ CVD events per $1000$ person-years.
• With therapy started at age $10$ and continued for life, this dropped to $11.4$ events per $1000$ person-years.
• That rate approached the general U.S. population rate for $10$-year-olds ($10.7$ events per $1000$ person-years), meaning early treatment can reduce long-term risk close to non-FH peers.

3. Delaying or stopping therapy worsened outcomes

Any strategy that delayed therapy or stopped it in young adulthood led to:

• More lifetime LDL exposure
• More heart attacks and strokes
• Fewer life years than continuous treatment started in childhood

Starting therapy at $18$ instead of $10$ still helped but prevented fewer events and added fewer life years than starting earlier.

What This Means in Practice

“The best approach to prevent premature cardiovascular disease in people with familial hypercholesterolemia is likely lipid-lowering therapy initiated during childhood.”

The authors emphasize supporting patients with FH through the transition from pediatric to adult care to avoid interruptions in treatment.

Practical steps for families and seniors

• Know your family history: Early heart attacks, strokes, or very high cholesterol in relatives can be clues to FH—ask about heart problems before age $55$ (men) or $65$ (women).
• Encourage testing: A simple cholesterol blood test can identify high LDL in children and adults; genetic evaluation may follow if FH is suspected.
• Support consistent treatment: If a child is started on lipid-lowering medication, staying on therapy long-term is crucial; the pediatric-to-adult care transition is a common drop-off point.